Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation

Abstract.  Objectives: The potential of epidermal growth factor receptor (EGFR)‐ and Her2‐targeted antibodies Cetuximab, Pertuzumab and Trastuzumab, used in combination to inhibit cell proliferation of breast cancer cells in vitro, has not been extensively investigated. It is anticipated that there...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Prolif
Hlavní autoři: Brockhoff, G., Heckel, B., Schmidt‐Bruecken, E., Plander, M., Hofstaedter, F., Vollmann, A., Diermeier, S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2007
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496387/
https://ncbi.nlm.nih.gov/pubmed/17635517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2184.2007.00449.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky